ALCHEMAB
LIVE

Serial Number

79403954

Owner

Alchemab Therapeutics Ltd

Attorney

James M. Theo

Filing Date

Jul 3, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ALCHEMAB Trademark

Serial Number: 79403954 • Registration: 8026498

ALCHEMAB is a trademark filed by Alchemab Therapeutics Ltd on July 3, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Alchemab Therapeutics Ltd (2 trademarks)

East Side Office 1.02,

Entity Type: 99

Trademark Details

Filing Date

July 3, 2024

Registration Date

November 18, 2025

Published for Opposition

September 30, 2025

Goods & Services

Pharmaceutical preparations incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; pharmaceutical preparations incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; Chemical preparations for medical and pharmaceutical purposes incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; antibodies for medical purposes; diagnostic preparations involving the testing and identification of antibodies for medical purposes; diagnostic preparations involving the testing of antibodies for medical purposes; diagnostic preparations involving the identification of antibodies for medical purposes.

Downloadable software for the testing of antibodies; downloadable software for the identification of antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibody technology.

Medical diagnostic services involving the testing of antibodies for medical purposes; medical diagnostic services involving the identification of antibodies for medical purposes; medical testing, analysis and diagnostic services in the field of antibodies; information, advisory and consultancy services in relation to all of the aforesaid.

Research and development services in the field of antibodies and antibody technology; drug development and discovery services in relation to pharmaceutical preparations incorporating antibodies and antibody technology; antibody discovery services in the nature of drug discovery services; development and testing of computing methods, algorithms and software for the testing and identification of antibodies; development and testing of computing methods, algorithms and software in the field of antibody technology; development and testing of computing methods, algorithms and software for use in or relating to the development of pharmaceutical preparations incorporating antibodies and antibody technology; information, advisory and consultancy services in relation to all of the aforesaid.

Filing History

FINAL DISPOSITION NOTICE SENT TO IB
Jun 4, 2026 FICS
FINAL DISPOSITION PROCESSED
Jun 4, 2026 FIMP
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Apr 14, 2026 NURC
CORRECTION UNDER SECTION 7 - PROCESSED
Mar 23, 2026 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 9, 2026 APRE
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 19, 2026 OPNX
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 18, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 4, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 4, 2026 OPNR
TEAS SECTION 7 REQUEST RECEIVED
Dec 9, 2025 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 18, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 18, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 30, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 30, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 24, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 28, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 28, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 28, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 28, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 28, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 6, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 6, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 6, 2025 TROA
REFUSAL PROCESSED BY IB
Mar 22, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 4, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 4, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 16, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jan 15, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 28, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 9, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 9, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 5, 2024 REPR